Mitoxantrone and cytotoxic drugs' mechanisms of action

Neurology

Volumn 74, Issue 1 SUPPL., 2010, Pages

  Vollmer, Timothy ^a,b   Stewart, Thomas ^b   Baxter, Nancy ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b Rocky Mountain MS Center   (United States)

^c Expert Medical Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLATIRAMER; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TERIFLUNOMIDE;

ABORTION; ADD ON THERAPY; ANEMIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFERTILITY; LEUKEMIA; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 74249113947     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c97f5a     Document Type: Article

References (42)

1. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31: 247-269.
2. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria, for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846.
3. Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005;64:1001-1007.
4. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 2007;68: 634-642.
5. Zivadinov R, Yella V, Dwyer MG, Hussein S, Cox JL. Evidence for cortical atrophy in patients with clinically isolated syndrome. Mult Scler 2006;12:S175.
6. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
7. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet 2002; 360:2018-2025.
8. Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14:663-670.
9. Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. ] Neurol 2006; 253:1160-1164.
10. Zaffaroni M, Rizzo A, Baldini SM, Ghezzi A, Comi G. Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis. Neurol Sci 2008; 29(suppl 2):S230-S232.
11. Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008;79:52-56.
12. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
13. Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 2005;11:573-582.
14. 14. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988;38(suppl 2):9-14. (Pubitemid 18172932)
15. Patti F, Reggio E, Palermo F, et al. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated, with, interferon beta plus cyclophosphamide followed by interferon beta. J Neurol 2004;251:1502-1506.
16. Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008;65:1044-1051.
17. Vermersch P, Waucquier N, Michelin E, et al. Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol 2007;14:85-89.
18. Novan trone [package insert]. Rockland, MA: EMD Serono; 2008.
19. Pattoneri P, Sozzi F, Pela G, et al. Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiography analysis. Echocardiography 2009;26:397-402.
20. Martinelli V. Incidence of acute leukemia, in multiple sclerosis patients treated with mitoxantrone: a multicenter retrospective study. Presented at the 61st Annual Meeting of the American Academy of Neurology; April 25-May 2, 2009; Seattle, WA. Abstract LB3.001.
21. Stillwell TJ, Benson RC Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients Cancer 1988;61:451-457.
22. Fisher GR, Patterson LH. DNA strand breakage by peroxidase-activated mitoxantrone. J Pharm Pharmacol 1991;43:65-66.
23. De Isabella P, Palumbo M, Sissi C, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 1995;48:30-38.
24. Thielmann HW, Popanda O, Gersbach H, Gilberg F. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in. UV-irradiated human fibroblasts. Carcinogenesis 1993;14:2341-2351.
25. Kopadze T, Dehmel T, Hartung H-P, Stiive O, Kieselcr BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells. Arch Neurol 2006;63:1572-1578.
26. Neuhaus O, Wiendl H, Kieseier BC, et al. Multiple sclerosis: immunological effects of mitoxantrone in vitro reveal antigen-presenting cells as major targets. Eur J Neurol 2002;9(suppl 2):130.
27. Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004;63(suppl):S15-S18.
28. Klioury SJ, Bharanidharan P, Bourcier K, et al. Immunologic effects of mitoxantrone therapy in patients with multiple sclerosis. Neurology 2002;58(suppl 3):A245-A246.
29. Fidler JM, Dejoy SQ, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986; 137:727-732.
30. Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 1991 ; 13:922-930.
31. Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002;8:142-154.
32. Strauss K, Hulstaert F, Deneys V, et al. The immune profile of multiple sclerosis: T-lymphocyte effects predominate over all other factors in cyclophosphamidc-treated patients. J Neuroimmunol 1995;63:133-142.
33. Invemizzi P, Benedetti MD, Poli S, Monaco S. Azathioprine in multiple sclerosis. Mini Rev Med Chem 2008; 8:919-926.
34. Imuran®(azathioprine) product information. San Diego, CA: Prometheus Laboratories Inc.; 2008.
35. Methotrexate for injection, USP, product information. Bedford, OH: Bedford Laboratories; 2005.
36. Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th cd. New York: McGraw-Hill; 2006.
37. Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000;2:1-23.
38. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
39. Mehling A, Grabbe S, Voskort M, Schwartz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165:2374-2381.
40. Jonsson CA, Carlsten H. Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol 2003;3:31-37.
41. Oest TM, Dehghani F, Korf HW, Hailer NP. The immunosuppressant mycophenolate mofetil improves preservation of the perforant path, in organotypic hippocampal slice cultures: a retrograde tracing study. Hippocampus 2006;16:437-442.
42. Dehghani F, Hischebeth GT, Wirjatijasa F, Kohl A, Korf HW, Hailer NP. The immunosuppressant mycophenolate mofetil attenuates neuronal damage after excitotoxic injury in hippocampal slice cultures. Eur J Neurosci 2003;18: 1061-1072.